
Constantine S. Tam, MD discusses long-term results of patients receiving Zanubrutinib in the Phase 3 ALPINE study confirm sustained benefit of Zanubrutinib in patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: Up to 6 years of follow-up with the long-term extension.





























